Neurofibromatosis

Gabriel Groisman Elected Chairman of the Board of the Children's Tumor Foundation

Retrieved on: 
Monday, December 26, 2022
NF, Partner, Centre for Social Justice Awards, Patient, Chairperson, Neoplasm, Severe cognitive impairment, Deafness, Hope, Neurofibromatosis, University, Children's Tumor Foundation, CTF, Learning, Schwannomatosis, JD, Government, National Executive Committee of the Labour Party, Executive Committee, Chair, Pursuit, Research, Cancer, Jewish Community Relations Council of Minnesota and the Dakotas, Radio, Volunteering, Pharmaceutical industry, Medicine, Hotel, Jews, Philosophy, Jurist

NEW YORK, Dec. 26, 2022 /PRNewswire-PRWeb/ -- The Board of Directors of the Children's Tumor Foundation (CTF) has unanimously elected Gabriel Groisman of Bal Harbour, Florida, as Chairman of the Board. First elected to the CTF Board in 2016, Mr. Groisman most recently served the Foundation as Vice-Chairman of the Board, and previously as Secretary. He has also served as Chair of the Community Relations and Government Engagement Committee of the Board.

Key Points: 
  • The Board of Directors of the Children's Tumor Foundation (CTF) has unanimously elected Gabriel Groisman of Bal Harbour, Florida, as Chairman of the Board.
  • NEW YORK, Dec. 26, 2022 /PRNewswire-PRWeb/ -- The Board of Directors of the Children's Tumor Foundation (CTF) has unanimously elected Gabriel Groisman of Bal Harbour, Florida, as Chairman of the Board.
  • First elected to the CTF Board in 2016, Mr. Groisman most recently served the Foundation as Vice-Chairman of the Board, and previously as Secretary.
  • "I am deeply grateful and humbled to have the support of the Board of the Children's Tumor Foundation to serve as its Chair," said Gabriel Groisman.

Chiropractic May Offer Relief From Complicated Chronic Headaches

Retrieved on: 
Monday, November 21, 2022
Tao, Signs and symptoms, Report, Postural orthostatic tachycardia syndrome, Pathology, Sensation, Neck, Neck pain, Pectus carinatum, Neurofibromatosis, Chronic pain, Pain scale, Lactic acid, History, Chiropractic, Foramen magnum, Spine, ECP, Multimedia, Dizziness, Patient, Head, Executive Committee, Bell's palsy, Radiculopathy, Academy of Family Physicians of India, Literature review, CRP, Dentistry, Poultry, Birth control, Healthcare, Online shopping, Headache

NEW YORK, Nov. 21, 2022 /PRNewswire/ -- Chiropractors may reduce the number of monthly neck pain and headaches for people who have chronic and complicated type of history, four case studies (1-4) published in 2022 American Journal of Case Reports, found.

Key Points: 
  • The researchers from Chiropractic Doctors Association of Hong Kong (CDAHK) released their case studies on chronic headaches and neck pain.
  • Chiropractors provide long-term relief from chronic headaches, said Eric Chu, principal investigator of the studies and Chairman of Chiropractic Doctors Association of Hong Kong.
  • "Our recent studies(4-12) have also found that chiropractic may be effective for episodic neck pain and chronic headaches.
  • Treating chronic pain is a multidisciplinary approach, and chiropractic is one of best treatment options that should be considered," Chu said.

Colbeck Capital Management Sponsors Children's Tumor Foundation's 2022 Gala

Retrieved on: 
Monday, November 14, 2022
Goldman Sachs, Innovation, Neurofibromatosis, NF, Greenwich Savings Bank Building, Severe cognitive impairment, Chronic pain, Hockey Humanitarian Award, CTF, Television, Deafness, View, Cancer, Children's Tumor Foundation, Partner, Research, Multimedia, Patient, Genetic disorder, Morgan Stanley, Johns Hopkins, Neoplasm, Neurosurgery, Oaktree Capital Management, Pharmaceutical industry, Medicine

NEW YORK, Nov. 14, 2022 /PRNewswire/ --Colbeck Capital Management continues its long-term support of the Children's Tumor Foundation (CTF) by sponsoring the upcoming 2022 National Gala .

Key Points: 
  • NEW YORK, Nov. 14, 2022 /PRNewswire/ --Colbeck Capital Management continues its long-term support of the Children's Tumor Foundation (CTF) by sponsoring the upcoming 2022 National Gala .
  • The gala will be hosted by actor and producer Jonathan Sadowski and television host Raina Seitel.
  • Colbeck Capital Management ( colbeck.com ) is a leading, middle-market private credit manager focused on strategic lending.
  • Colbeck sponsors its portfolio companies through consistent engagement with management teams in areas such as finance, capital markets and growth strategies, distinguishing itself from traditional lenders.

Colbeck Capital Sponsors The Children's Tumor Foundation Online Charity Poker Tournament

Retrieved on: 
Friday, October 7, 2022
Online, Children's Tumor Foundation, Spinal cord, Neoplasm, Research, Multimedia, Knowledge, Goldman Sachs, Neurofibromatosis, Genetic disorder, Health, CTF, Morgan Stanley, Deformity, EST, Brain, Chronic pain, Hearing, NF, View, Nervous system, Online gambling

NEW YORK, Oct. 7, 2022 /PRNewswire/ -- Colbeck Capital Management and co-founder Jason Colodne are proud to continue to support the Children's Tumor Foundation (CTF) as a sponsor for their upcoming Online Charity Poker Tournament .

Key Points: 
  • NEW YORK, Oct. 7, 2022 /PRNewswire/ -- Colbeck Capital Management and co-founder Jason Colodne are proud to continue to support the Children's Tumor Foundation (CTF) as a sponsor for their upcoming Online Charity Poker Tournament .
  • The poker tournament offers donors the opportunity to participate together in an evening of entertainment and competition while helping to bolster the CTF mission to end neurofibromatosis, or NF.
  • Colbeck Capital Management ( colbeck.com ) is a leading, middle-market private credit manager focused on strategic lending.
  • Colbeck sponsors its portfolio companies through consistent engagement with management teams in areas such as finance, capital markets and growth strategies, distinguishing itself from traditional lenders.

Researchers Unlock the Key and Identify Serious Pathology in Low Back Pain

Retrieved on: 
Friday, September 16, 2022
Case report, Pain scale, Policy, UNICEF, Woman, SIRVA, Patient, Technology, Academy of Family Physicians of India, EC, Research, PR, Chiropractic professional ethics, COVID-19, Prevalence, NEW, United Nations, Incidence, Streptococcus oralis, Opportunity, Dizziness, Science, Doctor of Philosophy, Systematic, Health care, Signs and symptoms, Gingivitis, Breast cancer, Architecture, Systematic review, Medical Science Monitor, Neck pain, Pathology, Association, Low back pain, Deformity, Literature review, Literature, Neurofibromatosis, Bell's palsy, Parkinson's disease, Osteoporosis, Cancer, Quality of life, Vaccination, Multimedia, Neck, Medical device, Healthcare, Renewable energy, Poultry, Pharmaceutical industry, Birth control, Online shopping, Chiropractic, Headache

NEW YORK, Sept. 16, 2022 /PRNewswire/ -- "One benefit from this type of analysis is that it provides an opportunity to engage in more directed discussions aimed at confronting these serious pathology presenting as low back pain, which may have the potential to provide long-term health benefits to healthcare policy," Eric Chun-Pu Chu, PhD, investigator and chairman from the Chiropractic Doctors Association of Hong Kong (CDAHK).

Key Points: 
  • Investigators from the CDAHK, had resolve the puzzle and estimate the prevalence and types of serious pathology among adults with low back pain.
  • The study found that serious pathology was uncommon among adults with new low back pain presenting for chiropractic care.
  • The current research will guide the clinicians in identifying serious pathology, such as cancer, more often in the chiropractic clinics.
  • Prevalence of Serious Pathology Among Adults with Low Back Pain Presenting for Chiropractic Care: A Retrospective Chart Review of Integrated Clinics in Hong Kong.

Don't Confuse Monkeypox with This Medical Condition That Affects Over 250,000 People

Retrieved on: 
Thursday, September 8, 2022
University, University of Pittsburgh Medical Center, Monkeypox, Medicine, Research, Washington University School of Medicine, Parent, Skin, Diagnosis, Foundation, Nerve, Mental health, Neoplasm, NF1, Face, Annual Review of Cancer Biology, Learning difficulties, Torso, Family, Social media, Medical imaging, Pharmaceutical industry, MD, Dermatology, Neurofibromatosis

DUNCANSVILLE, Pa., Sept. 8, 2022 /PRNewswire/ -- There is a growing trend on social media to publicly shame individuals with visible bumps and raised tumors, and immediately assume the individual has Monkeypox. However, that isn't true. Approximately 250,000 people worldwide have a condition call NF1, or Neurofibromatosis, a genetic condition which causes small tumors to grow on nerve endings, creating fleshy bumps on and underneath the skin.

Key Points: 
  • Approximately 250,000 people worldwide have a condition call NF1, or Neurofibromatosis, a genetic condition which causes small tumors to grow on nerve endings, creating fleshy bumps on and underneath the skin.
  • Monkeypox is characterized by painful, hard or pus-filled lesions on the skin that actually scab and fall off.
  • At age 5, a neurologist finally diagnosed Giorgio with a rare condition, neurofibromatosis type 1 or NF1.
  • "We partner with researchers that have a proven record of modeling NF1 and progressing existing research of the condition.

Worldwide Melanoma Treatment Industry to 2027 - Players Include Novartis, Pfizer, Sanofi and AstraZeneca - ResearchAndMarkets.com

Retrieved on: 
Tuesday, July 12, 2022
Surgery, Health, Oncology, Disease, Income, Celgene, Prevalence, Bristol Myers Squibb, GlaxoSmithKline, Novartis, Acquisition, Incidence, Health, Therapy, Cobimetinib, Comorbidity, III, Risk, Neurofibromatosis, Sequah Medicine Company, Patient, Selumetinib, Ovarian cancer, Government, COVID-19, AstraZeneca, Lists of diseases, Neoplasm, Amgen, Encorafenib, FDA, Melanoma, NF1, Growth, Merck, Pharmaceutical industry

The "Melanoma Treatment Market - Forecasts from 2022 to 2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Melanoma Treatment Market - Forecasts from 2022 to 2027" report has been added to ResearchAndMarkets.com's offering.
  • These changes are increasing the incidence of melanoma patients worldwide, raising the demand for proper methods of treatment.
  • By type, cutaneous melanoma is widely spread globally caused by too much exposure to ultraviolet rays from the sun and indoor tanning.
  • Merck joined AstraZeneca in developing and commercializing Koselugo as part of a deal that included the ovarian cancer drug Lynparza.

Ashvattha Therapeutics Announces Presentation of Preclinical Data at the 2022 Neurofibromatosis (NF) Conference Demonstrating the Potential of Hydroxyl Dendrimer Therapeutics to Reduce Toxicity in Targeted Treatment of Plexiform Neurofibroma

Retrieved on: 
Tuesday, June 21, 2022
NF1, Skin, American Academy, Lists of diseases, Therapy, Pediatrics (journal), Microglia, Safety, Neurofibromatosis type I, Tumor-associated macrophage, Neuron, HDT, Technology, HD, Tumor microenvironment, Inherited disorders of trafficking, CEO, Diabetic retinopathy, Toxicity, Johns Hopkins University, Indiana University School of Medicine, HDS, Brain, AMD, Neuro, Inflammation, Ophthalmology, Neurofibroma, Growth, Disease, Neurofibromatosis, TME, Ashvattha, Dendrimer, DME, NF, Patient, Neoplasm, Pigment, Conference, Macrophage, Neurology, GLOBE, PNF, Tams, PSFS Building, Pharmaceutical industry

The data was presented by Emma C. Mazurek, a scientific collaborator at Indiana University School of Medicine, in a poster titled, Hydroxyl Dendrimer Therapeutics Reduce Toxicity in Targeted Delivery to Plexiform Neurofibroma.

Key Points: 
  • The data was presented by Emma C. Mazurek, a scientific collaborator at Indiana University School of Medicine, in a poster titled, Hydroxyl Dendrimer Therapeutics Reduce Toxicity in Targeted Delivery to Plexiform Neurofibroma.
  • Notably, the smaller HD (~14 kDa) showed greater uptake in tumor associated macrophages and microglia, than the larger HD (~56 kDa).
  • These results suggest that by conjugating drugs to HDs theres potential to improve safety and reduce toxicity associated with current treatments for NF.
  • Ashvattha Therapeutics is a clinical-stage biotech company developing novel hydroxyl dendrimer therapeutics (HDTs) targeting unmet medical needs in neurology, ophthalmology, inflammatory diseases and neuro-oncology.

Jason Colodne and Jason Beckman, Co-Founders and Managing Partners of Colbeck Capital Support The Children's Tumor Foundation's Virtual Research Reception

Retrieved on: 
Tuesday, June 14, 2022
Goldman Sachs, View, Lists of diseases, Conference, Research, Disability, Schwannomatosis, Doctor of Philosophy, NF, Neurofibromatosis, Multimedia, Annual, Children's Tumor Foundation, Deformity, Nervous system, Morgan Stanley, Chronic pain, Neoplasm, Pharmaceutical industry

NEW YORK, June 14, 2022 /PRNewswire/ --Colbeck Capital Management, a leading middle-market private credit manager focused on strategic lending, along with its co-founders Jason Colodne and Jason Beckman, continue to support the Children's Tumor Foundation and its Virtual Research Reception.

Key Points: 
  • NEW YORK, June 14, 2022 /PRNewswire/ --Colbeck Capital Management, a leading middle-market private credit manager focused on strategic lending, along with its co-founders Jason Colodne and Jason Beckman, continue to support the Children's Tumor Foundation and its Virtual Research Reception.
  • The event is designed to provide a preview of the research intended for presentation at the annual NF Conference.
  • The hour-long virtual event also included the opportunity for attendees to ask questions of both presenters.
  • The Annual NF Conference is the largest gathering of NF clinicians, researchers, and professionals in the world.

Ashvattha Therapeutics Announces Poster Presentation of Preclinical Data on Hydroxyl Dendrimer-Based Therapeutics at the 2022 Neurofibromatosis (NF) Conference

Retrieved on: 
Tuesday, June 7, 2022
Neurofibromatosis, HDS, PSFS Building, Conference, Toxicity, Johns Hopkins University, Inflammation, NF, Disease, Neurofibromatosis type I, AMD, Therapy, Diabetic retinopathy, NF1, Neuro, HDT, Ophthalmology, GLOBE, Neurology, Technology, COVID-19, DME, Ashvattha, Pharmaceutical industry

REDWOOD CITY, Calif., June 07, 2022 (GLOBE NEWSWIRE) -- Ashvattha Therapeutics (Ashvattha), a clinical stage company developing novel hydroxyl dendrimer therapeutics, today announced a poster presentation of preclinical data demonstrating its hydroxyl dendrimer-based therapeutics reduce toxicity in targeted delivery to plexiform neurofibroma, a slow growing tumor associated with neurofibromatosis type 1 (NF1), at the 2022 Neurofibromatosis (NF) Conference hosted by the Childrens Tumor Foundation and taking place at Loews Philadelphia Hotel in Philadelphia, PA, June 18 21, 2022.

Key Points: 
  • REDWOOD CITY, Calif., June 07, 2022 (GLOBE NEWSWIRE) -- Ashvattha Therapeutics (Ashvattha), a clinical stage company developing novel hydroxyl dendrimer therapeutics, today announced a poster presentation of preclinical data demonstrating its hydroxyl dendrimer-based therapeutics reduce toxicity in targeted delivery to plexiform neurofibroma, a slow growing tumor associated with neurofibromatosis type 1 (NF1), at the 2022 Neurofibromatosis (NF) Conference hosted by the Childrens Tumor Foundation and taking place at Loews Philadelphia Hotel in Philadelphia, PA, June 18 21, 2022.
  • Poster presentation details can be found below:
    Ashvattha Therapeutics is a clinical-stage biotech company developing novel hydroxyl dendrimer therapeutics (HDTs) targeting unmet medical needs in neurology, ophthalmology, inflammatory diseases, and neuro-oncology.
  • The therapies are based on hydroxyl dendrimers (HDs), a targeted platform technology exclusively licensed from our founders, Kannan Rangaramanujam and Sujatha Kannan at Johns Hopkins University.
  • HDs chemically conjugated to disease modifying drugs create novel proprietary HD therapeutics (HDTs) selectively targeting reactive inflammatory cells in disease tissue with localized sustained effects.